Focused On-demand Library for Elongation factor 1-alpha 1

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P68104

UPID:
EF1A1_HUMAN

ALTERNATIVE NAMES:
Elongation factor Tu; Eukaryotic elongation factor 1 A-1; Leukocyte receptor cluster member 7

ALTERNATIVE UPACC:
P68104; P04719; P04720; Q6IQ15

BACKGROUND:
Elongation factor 1-alpha 1, with alternative names such as Elongation factor Tu and Leukocyte receptor cluster member 7, is essential for the translation of viral proteins, including during SARS-CoV-2 infection. It ensures the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes, a critical step in the elongation phase of protein synthesis. Additionally, EF1A1's role in IFNG transcription regulation underscores its importance in immune responses.

THERAPEUTIC SIGNIFICANCE:
The pivotal role of Elongation factor 1-alpha 1 in protein synthesis and viral replication, including its requirement for SARS-CoV-2 protein translation, underscores its potential as a target for therapeutic intervention. Exploring EF1A1's functions could lead to groundbreaking treatments for infectious diseases and conditions related to protein synthesis dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.